[{"id":"7eb4804e-e312-4742-a59c-d9255aa4ec24","acronym":"","url":"https://clinicaltrials.gov/study/NCT05475184","created_at":"2022-07-26T17:10:16.436Z","updated_at":"2024-07-02T16:36:06.660Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor","source_id_and_acronym":"NCT05475184","lead_sponsor":"Onconic Therapeutics Inc.","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nesuparib (JPI-547)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2022-07-26"}]